oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
IE produces both intracardiac effects - eg, valvular insufficiency and a wide variety of systemic effects, both from emboli (sterile and infected) and a variety of immunological mechanisms.
It is a disease that is easily overlooked or misdiagnosed and clinicians should be vigilant and well versed in the manifestations of IE to avoid missing the diagnosis.
- The incidence of infective endocarditis is approximately 1.7-6.2 cases per 100,000 patient years, although rates are higher in at-risk cohorts such as intravenous drug users. Incidence has remained constant for 50 years despite changes in the factors affecting incidence.
- Figures for incidence are similar between countries. It is three times more common in men and increasing in elderly patients (25-50% of cases occur in the over-60s) often associated with other disease - eg, diabetes, cancer, alcoholism.
Cardiac conditions considered to increase a patient's risk of developing infective endocarditis:
- Valvular heart disease with stenosis or regurgitation.
- Valve replacement.
- Structural congenital heart disease, including surgically corrected or palliated structural conditions, but excluding:
- Isolated atrial septal defect.
- Fully repaired ventricular septal defect.
- Fully repaired patent ductus arteriosus.
- Closure devices that are judged to be endothelialised.
- Previous infective endocarditis.
- Hypertrophic cardiomyopathy.
Other risk factors include recreational drug abuse and invasive vascular procedures.
All cases have a nonbacterial thrombotic endocarditis (a sterile fibrin-platelet vegetation) as the prerequisite for adhesion and invasion. The site of this thrombus is influenced by the Venturi effect, with deposition of thrombus on the low pressure side. There are differences in the different clinical situations:
The thrombus may be produced either by the invading organism or by valvular trauma (pacing wires, catheters, etc).
Sufficient inoculum of bacteria required to allow invasion of the thrombus, bacteria clumping with production of agglutinating antibodies.
Nonbacterial thrombotic endocarditis:
This can result from, for example, renal failure, neoplasia, systemic lupus erythematosus (SLE) or malnutrition.
The valves most commonly affected by IE are (in decreasing order of frequency):
- Mitral valve.
- Aortic valve.
- Combined mitral and aortic valve.
- Tricuspid valve.
- Pulmonary valve - rare.
The organisms responsible for infective endocarditis
- Staphylococcus aureus:
The most common cause of IE overall (acute and subacute); most common with prosthetic valves, acute IE, and IE related to intravenous drug abuse. High mortality rate.
Coagulase negative S. aureus: causes subacute disease similar to Streptococcus viridans. Accounts for 30% of IE associated with prosthetic valves.
- S. viridans:
50-60% of subacute IE cases.
- Group D streptococci:
Usually subacute and the third most common cause of IE.
- Streptococcus intermedius:
Acute and subacute infection. Causes 15% of all cases of IE.
- Group A, C and G streptococci:
Acute IE is similar to that with S. aureus. High mortality (up to 70%).
- Group B streptococci:
Acute disease, high mortality often requiring valve replacement. Occurs in pregnancy and the elderly particularly.
- S. viridans:
- Pseudomonas aeruginosa:
Usually acute IE and requires surgery for cure.
- HACEK organisms (Haemophilus spp., Aggregatibacter actinomycetemcomitans, Cardiobacterium spp., Eikenella corrodens, Kingella kingae):
Usually subacute disease and about 5% of all IE.
Cause subacute disease.
See also the separate article Cardiovascular History and Examination.
- The clinical presentation is very variable. A high index of suspicion and low threshold for investigation to exclude IE are therefore essential in at-risk groups.
- It may present as an acute, rapidly progressive infection, but also as a subacute or chronic disease, with nonspecific symptoms - eg, fatigue, low-grade fever, flu-like illness, polymyalgia-like symptoms, loss of appetite, back pain, pleuritic pain, abdominal symptoms (may be pain, vomiting and appendicitis-like symptoms) and weight loss.
- The majority of patients present with fever, often associated with systemic symptoms of chills, poor appetite and weight loss.
- Heart murmurs are found in up to 85% and new murmurs have been recently reported in 48% of patients.
- Classic textbook signs may still be seen in the developing world, but are increasingly uncommon in developed countries because patients present at an early stage of the disease.
- Immunological phenomena, such as splinter haemorrhages, Roth's spots and glomerulonephritis, are now less common, but emboli to brain (cerebrovascular accident), lung or spleen occur in 30% of patients and are often the presenting feature.
- May present with congestive cardiac failure
- Atypical presentation (eg, no fever) is more common in the elderly, after antibiotic pre-treatment, in the immunocompromised patient and in IE involving less virulent or atypical organisms.
- The diagnosis of IE should also be considered in patients who present with a stroke or transient ischaemic attack and a fever.
- Fever: elderly, chronically ill patients with subacute IE may not have fever, but the majority do.
- Heart murmurs:
- Most patients have a murmur.
- Exception is right-sided IE where one third have murmurs.
- Only 15% have the classic 'changing murmur'.
- The most common murmur is aortic regurgitation.
- Hands and feet (dorsum).
- Chest and abdominal wall.
- Oral mucosae and soft palate.
- Splinter or subungual haemorrhages: Linear and red.
- Osler's nodes: small tender red-to-purple nodules on the pulp of the terminal phalanges of the fingers and toes
- Clubbing: only 10% of cases and usually in long-standing subacute IE.
- Roth's spots: retinal haemorrhages with pale centres.
- Janeway's lesions: irregular painless erythematous macules on the thenar and hypothenar eminence (usually with acute IE and S. aureus).
- With subacute IE, usually asymmetric and up to three joints affected (fluid sterile).
- Acute IE can give acute septic monoarticular arthritis.
- Splenomegaly: most often observed in long-standing subacute disease and often persists after treatment.
- Meningism/meningitis: purulent disease occurs in acute IE and aseptic variety in subacute IE.
Criteria for consideration and investigation of possible infective endocarditis
- A febrile illness and a murmur of new valvular regurgitation.
- A febrile illness, a pre-existing at-risk cardiac lesion (see 'Risk factors', above) and no clinically obvious site of infection.
- A febrile illness associated with any of:
- Predisposition and recent intervention with associated bacteraemia.
- Evidence of congestive heart failure.
- New conduction disturbance.
- Vascular or immunological phenomena: embolic event, Roth's spots, splinter haemorrhages, Janeway's lesions, Osler's nodes.
- A new stroke.
- Peripheral abscesses (renal, splenic, cerebral, vertebral) of unknown cause.
- A protracted history of sweats, weight loss, anorexia or malaise and an at-risk cardiac lesion (see 'Risk factors', above).
- Any new unexplained embolic event (eg, cerebral or limb ischaemia).
- Unexplained, persistently positive blood cultures.
- Intravascular catheter-related bloodstream infection with persistently positive blood cultures 72 hours after catheter removal.
Patients present to a variety of specialists who may consider a range of alternative diagnoses, including chronic infection, rheumatological and autoimmune disease or malignancy. Some of the more unusual diseases which may also have similar complex and varied manifestations include:
- Atrial myxoma and other cardiac neoplasms.
- Lyme disease.
- Antiphospholipid syndrome.
- Polymyalgia rheumatica.
- Reactive arthritis.
Presentions that may cause difficulty with diagnosis include:
- Acute meningitis - signs and symptoms but with sterile CSF.
- Hemiplegia from emboli in the middle cerebral artery (50% of patients may be first manifestation; has high mortality).
- Renal infarcts causing painless haematuria.
- Splenic infarction causing pain.
- Blindness from retinal artery occlusion.
- Myocardial infarction from emboli in the coronary artery.
- Pulmonary emboli.
- Interstitial nephritis or proliferative glomerulonephritis from deposition of circulating immune complexes.
- Acute kidney injury or chronic kidney disease which may result.
- Musculoskeletal symptoms (nearly half of patients) - often from immunologically mediated synovitis.
- Immune-mediated vasculitis (causing Osler's nodes and Roth's spots).
- Palpitations from immune-mediated myocarditis.
- Back pain (15% of patients) may have origin in immune complex deposition in disc spaces.
- Nonspecific signs of infection - eg, elevated CRP or ESR, leukocytosis, anaemia and microscopic haematuria.
- CXR: as part of the initial assessment.
- Electrocardiogram is useful to detect the 10% of patients who will develop conduction defects.
- Blood cultures:
- Should be taken prior to starting treatment in all cases. Meticulous aseptic technique is required.
- In patients with a chronic or subacute presentation, three sets of blood cultures should be taken from peripheral sites with at least six hours between them prior to commencing antimicrobial therapy.
- In patients with suspected IE and severe sepsis or septic shock at the time of presentation, two sets of blood cultures should be taken at different times within one hour prior to commencement of empirical therapy.
- Bacteraemia is continuous in IE rather than intermittent, so positive results from only one set out of several blood cultures should be regarded with caution.
- If a stable patient has suspected IE but is already on antibiotic treatment, consideration should be given to stopping treatment and performing three sets of blood cultures off antibiotics.
- Antibiotic therapy may need to be stopped for 7-10 days before blood cultures become positive.
- Routine incubation of blood cultures for more than seven days is not necessary. Once a microbiological diagnosis has been made, routine repeat blood cultures are not recommended. Blood cultures should be repeated if a patient is still febrile after seven days of treatment.
- When the causative micro-organism has been isolated, the minimum inhibitory concentration (MIC) of the chosen antimicrobial should be established.
- Echocardiography must be performed as soon as possible (ideally within 24 hours) in all patients with suspected IE.
- Transthoracic echocardiography (TTE) is the initial investigation of choice. In cases with an initially negative TTE/transoesophageal echocardiography (TOE) examination, repeat TTE/TOE should be performed 7-10 days later if the clinical suspicion of IE remains high.
- All patients with S. aureus bacteraemia or candidaemia require echocardiography (ideally within the first week of treatment or within 24 hours if there is other evidence to suggest IE).
- TTE is recommended at completion of antibiotic therapy for evaluation of cardiac and valve morphology and function. Follow-up echocardiography should be performed if there is evidence of cardiac complications or a suboptimal response to treatment.
- In patients with blood culture-negative IE, serological testing for Coxiella and Bartonella species should be performed.
- Consider brucellosis in patients with negative blood cultures and a risk of exposure (dietary, occupational or travel).
- Candida antibody and antigen tests should not be used to diagnose candidal IE because there is currently no evidence to support their use and therefore relying on these tests may lead to inappropriate treatment.
- Investigation of excised heart valves:
- Samples of valve or other infected tissue removed at the time of surgery should be sent for microbiological and histopathological investigation.
- Samples of excised heart valve (or tissue from embolectomy) from cases of culture-negative IE should be referred for broad-range bacterial PCR and sequencing.
Modified Duke criteria for diagnosis of infective endocarditis: clinical criteria for definite infective endocarditis requires two major criteria, one major and three minor criteria, or five minor criteria.
- Positive blood culture for IE: typical micro-organism consistent with IE from two separate blood cultures.
- Evidence of endocardial involvement:
- Positive echocardiogram for IE:
- oscillating intracardiac mass on valve or supporting structures, in the path of regurgitant jets, or on implanted material in the absence of an alternative anatomical explanation, or
- abscess, or
- new partial dehiscence of prosthetic valve), or
- new valvular regurgitation (worsening or changing of pre-existing murmur not sufficient).
- Positive echocardiogram for IE:
- Predisposition: predisposing heart condition or intravenous drug use.
- Fever: temperature >38°C.
- Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial haemorrhage, conjunctival haemorrhages and Janeway's lesions.
- Immunological phenomena: glomerulonephritis, Osler's nodes, Roth's spots and rheumatoid factor.
- Microbiological phenomena: positive blood culture but does not meet a major criterion as noted above or serological evidence of active infection with organism consistent with IE.
- PCR: broad-range PCR of 16S.
- Echocardiographic findings consistent with IE but do not meet a major criterion as noted above.
Have a high index of suspicion. Admit any patient with suspected IE to hospital for full investigation. A cardiologist and infection specialist should be closely involved in the diagnosis, treatment and follow-up of patients with IE.
Oral therapy for endocarditis has been used but is rarely advocated in guidelines because of concerns about efficacy. In general, intravenous therapy is recommended to ensure adequate dosing and administration. Occasionally, especially in intravenous drug users, problems obtaining or maintaining safe intravenous access mean that oral therapy may be the safest treatment option. Agents with oral bioavailability that is close to that achieved with intravenous administration can be given. Ciprofloxacin, linezolid and rifampicin have excellent oral bioavailability.
Home/community/outpatient intravenous therapy is an appropriate method for managing selected patients with IE - eg, those who are stable and responding well to therapy without signs of heart failure, have no indications for surgery (see below) and no uncontrolled extracardiac foci of infection. S. aureus is associated with highest mortality and complications, and caution is therefore advised where this is the cause. Ceftriaxone, teicoplanin, daptomycin and vancomycin are suitable agents for home/community/outpatient therapy for endocarditis.
Initial empirical therapy while awaiting culture results
- Native valve endocarditis (NVE) - indolent presentation: amoxicillin AND (optional) gentamicin. The role of gentamicin is controversial before culture results are available.
- NVE, severe sepsis (no risk factors for Enterobacteriaceae, Pseudomonas spp.): vancomycin (if allergic to vancomycin, replace with daptomycin) AND gentamicin. If there are concerns about nephrotoxicity/acute kidney injury, use ciprofloxacin in place of gentamicin.
- NVE, severe sepsis AND risk factors for multiresistant Enterobacteriaceae, Pseudomonas spp: vancomycin AND meropenem.
- Prosthetic valve endocarditis (PVE): pending blood cultures or with negative blood cultures: vancomycin AND gentamicin AND rifampicin.
Intravenous therapy for four weeks is recommended for staphylococcal NVE, which should be extended to at least six weeks in patients with intracardiac prostheses, secondary lung abscesses and osteomyelitis. Routine switch to oral antimicrobials is not recommended.
- NVE, meticillin-susceptible staphylococci: flucloxacillin.
- NVE, meticillin-resistant: vancomycin AND rifampicin.
- NVE, meticillin-resistant, vancomycin-resistant: daptomycin AND rifampicin OR gentamicin.
PVE, methicillin, rifampicin-susceptible staphylococci: flucloxacillin AND rifampicin AND gentamicin
- PVE, meticillin-resistant, vancomycin-susceptible or penicillin allergy: vancomycin AND rifampicin AND gentamicin.
- PVE, meticillin-resistant, vancomycin-resistant: daptomycin AND rifampicin AND gentamicin.
- Benzylpenicillin monotherapy; ceftriaxone monotherapy; benzylpenicillin AND gentamicin; ceftriaxone AND gentamicin.
- Treatment of streptococci in patients with significant penicillin allergy: vancomycin AND gentamicin; teicoplanin AND gentamicin.
- Amoxicillin OR penicillin AND gentamicin; vancomycin AND gentamicin; teicoplanin AND gentamicin; amoxicillin (for amoxicillin-susceptible AND high-level gentamicin resistant isolates).
- Treatment should be with a b-lactamase-stable cephalosporin or amoxicillin if the isolate is susceptible.
- Gentamicin should only be added for the first two weeks of therapy.
- Ciprofloxacin can be considered as an alternative agent.
- NVE should receive four weeks and PVE six weeks of treatment.
- Doxycycline and hydroxychloroquine (both antibiotics for at least 18 months and up to four years).
- Doxycycline and ciprofloxacin (for at least three years)
- Amoxicillin AND gentamicin (if penicillin-allergic then use tetracycline).
- Doxycycline AND gentamicin.
Antifungal agents used include fluconazole, voriconazole, amphotericin, micafungin, caspofungin, anidulafungin, posaconazole and flucytosine. Itraconazole should not be used.
Initial treatment should be with an echinocandin or amphotericin. Surgical valve replacement is recommended.
Initial treatment should be with voriconazole. Surgical valve replacement is mandatory for survival.
A surgical opinion should be sought at the earliest opportunity for every patient with endocarditis affecting intracardiac prosthetic material.
Antibiotics are the standard treatment for native valve IE, with surgery primarily reserved for patients with heart failure or inadequate response to antibiotic treatment.
The timing and indications for surgical intervention to prevent systemic embolism in IE remain controversial. A recent trial to compare clinical outcomes of early surgery and conventional treatment in patients with left-sided IE, severe valve disease, and large vegetations found that early surgery in patients with IE and large vegetations significantly reduced mortality from embolic events by effectively decreasing the risk of systemic embolism.
A surgical opinion should be sought for any of the following indications:
Aortic or mitral IE with:
- Severe acute regurgitation or valve obstruction causing refractory pulmonary oedema/shock (emergency).
- Fistula into a cardiac chamber or pericardium causing refractory pulmonary oedema/shock (emergency).
- Severe acute regurgitation or valve obstruction and persisting heart failure or echocardiographic signs of poor haemodynamic tolerance (urgent).
- Severe regurgitation and no heart failure (elective).
- Locally uncontrolled infection including abscess, false aneurysm, enlarging vegetation (urgent).
- Persisting fever and positive blood culture for at least ten days after commencing appropriate antimicrobial therapy (urgent).
- Infection caused by fungi or multiresistant micro-organisms (urgent/elective).
Prevention of embolism
- Aortic or mitral IE with large vegetations (>10 mm) resulting in one or more embolic episodes despite appropriate antibiotic therapy (urgent).
- Aortic or mitral IE with large vegetations (>10 mm) and other predictors of complicated course like heart failure, persistent infection or abscess (urgent).
- Isolated very large vegetations >15 mm (urgent).
These are an inherent part of the progression of the disease. Potential complications of IE include:
- Myocardial infarction, pericarditis, cardiac arrhythmias.
- Heart valve insufficiency.
- Congestive heart failure.
- Sinus of Valsalva aneurysm.
- Aortic root or myocardial abscesses.
- Arterial emboli, infarctions, mycotic aneurysms.
- Arthritis, myositis.
- Glomerulonephritis, acute kidney disease.
- Stroke syndromes.
- Mesenteric or splenic abscess or infarction.
This varies markedly according to a variety of factors.
- S. viridans 98% cure rate.
- S. aureus 60-70% cure rate with worse results in those NOT abusing intravenous drugs.
- Fungal infections - cure rate less than 50%.
- Cure rates at least 10% lower than above for each variety.
- Surgery needed more often.
- Mortality rates in NVE range from 16-27%. Mortality rates in patients with PVE are higher.
- Increased mortality rates are associated with increased age, infection involving the aortic valve, development of congestive heart failure, central nervous system complications, and underlying disease - eg, diabetes.
- Mortality rates also vary with the infecting organism:
- Acute endocarditis due to S. aureus is associated with a high mortality rate (30-40%), except when it is associated with intravenous drug use.
- Endocarditis due to streptococci has a mortality rate of approximately 10%.
See separate article Prevention of Endocarditis for details.
Further reading & references
- Antimicrobial prophylaxis against infective endocarditis, NICE Clinical Guideline (March 2008)
- British National Formulary
- Management of Valvular Heart Disease, European Society of Cardiology (2012)
- British Heart Foundation
- Beynon RP, Bahl VK, Prendergast BD. Infective endocarditis. BMJ. August 2006.
- Hoen B; Epidemiology and antibiotic treatment of infective endocarditis: an update. Heart. 2006 Nov;92(11):1694-700.
- Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults, British Society for Antimicrobial Chemotherapy (2012)
- 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease; American College of Cardiology/American Heart Association Task Force on Practice Guidelines
- Kang DH, Kim YJ, Kim SH, et al; Early surgery versus conventional treatment for infective endocarditis. N Engl J Med. 2012 Jun 28;366(26):2466-73. doi: 10.1056/NEJMoa1112843.
- Brusch JL et al; Infective Endocarditis, Medscape, Sep 2012
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
|Original Author: Dr Richard Draper||Current Version: Dr Colin Tidy||Peer Reviewer: Dr Hannah Gronow|
|Last Checked: 20/11/2012||Document ID: 1698 Version: 24||© EMIS|